Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

Abstract Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the treatment of acute lymphoblastic leukemia (ALL). The t(4;11)(q21;q23) chromosomal translocation that leads to the expr...

Full description

Bibliographic Details
Main Authors: Tyler W. Jenkins, Sondra L. Downey-Kopyscinski, Jennifer L. Fields, Gilbert J. Rahme, William C. Colley, Mark A. Israel, Andrey V. Maksimenko, Steven N. Fiering, Alexei F. Kisselev
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-90451-9

Internet

https://doi.org/10.1038/s41598-021-90451-9

Similar Items